Vertex Pharmaceuticals to seek regulatory OK for telaprevir hepatitis drug in 2nd half of 2010

By AP
Monday, January 11, 2010

Vertex to ask for telaprevir OK later in 2010

CAMBRIDGE, Mass. — Biotechnology company Vertex Pharmaceuticals Inc. said Monday it plans to seek regulatory approval of the experimental hepatitis C drug telaprevir as scheduled during the second half of 2009.

Telaprevir is one of several potential hepatitis C treatments in development. If approved, it could face competition from Schering-Plough Corp.’s experimental hepatitis C drug boceprevir.

Meanwhile, the company will tell investors at a conference it expects a loss of less than $650 million in fiscal 2009, versus a loss of $459.9 million in fiscal 2008, or $397.5 million on an adjusted basis.

Vertex has about $1.3 billion in cash, cash equivalents and marketable securities.

The company will report 2009 financial results and provide a 2010 outlook on Feb. 4.

Shares of Vertex rose $1.28, or 3.2 percent, to $41.95 in midday trading.

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :